Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00205647
Status:
COMPLETED
Last Update Posted:
2017-11-06
First Post:
2005-09-13
Brief Title:
Study of Expectorant Activity of Oral N-acetylcystein NAC in Patients With Stable Chronic Bronchitis
Sponsor:
Wake Forest University
Organization:
Wake Forest University Health Sciences
Study Overview
Official Title:
A Phase II Multicenter Efficacy Safety and Dose-Effect Study of the Expectorant Activity of Oral N-acetylcystein NAC in Patients With Stable Chronic Bronchitis
Status:
COMPLETED
Status Verified Date:
2000-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randonmized masked placebo-controlled parallel group clinical trial to evaluate the effects of three different doses of N-acetyl L-cysteine NAC and placebo on patient safety and on physical and transport properties of expectorated sputum Patient sumptoms quality of life and exacerbation will also be followed as well as pulmonary function testing and functional exercise capacity We hypothesized that a prolongeed course of oral NAC favorably affects the morbidity of chronic bronchitis particularly the incidence of acute exacerbations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None